期刊文献+

c-Met siRNA对U87-EGFRvⅢ胶质瘤细胞凋亡和增殖的影响 被引量:1

The effects of c-Met siRNA on apoptosis and proliferation of U87-EGFRvⅢ glioma cells
下载PDF
导出
摘要 目的:合成针对c-Met的小干扰RNA(siRNA),研究其对U87-EGFRvⅢ(表皮生长因子受体Ⅲ型突变体)胶质瘤细胞凋亡和增殖的影响。方法:用脂质体转染合成的c-Met siRNA入U87-EGFRvⅢ细胞,未转染组为对照组,荧光实时定量PCR和Western blotting分别检测c-Met基因和蛋白的表达,MTT和Annexin V-FITC/PI法检测细胞增殖和凋亡情况。结果:c-Met siRNA明显抑制c-Met表达(P<0.05);明显增加细胞凋亡率(P<0.05)。同时,c-Met siRNA单独或协同EGFRvⅢsiRNA可抑制胶质瘤细胞增殖(P<0.05)。结论:c-Met siRNA可抑制U87-EGFRvⅢ胶质瘤细胞增殖、诱导其凋亡,为研究c-Met基因在胶质瘤中的作用及其靶向联合治疗提供了理论基础。 Objective To synthetize the small interfering RNA(siRNA) of c-Met and study its effects on apoptosis and proliteration of U87-EGFRv m glioma cells. Methods The synthesized e-Met siRNA was transfeeted into U87-EGFRvm cells by Lipofeetamine, non-transfection cells were control group. The expressions of c-Met gene and protein were tested by real time PCR and Western blotting.The cell proliferation and apoptosis were detected by. MTT and Annexin V-FITC/P1 assays respectively. Results c-Met siRNA significantly inhibited the expression of c-Met(P 〈 0.05); c-Met siRNA significantly increased the cell apoptotie rates(P 〈 0.05). Meanmile, c-Met siRNA alone or with EGFRvmsiRNA could inhibit the growth of glioma cells (P 〈 0.05). Conclusion e-Met siRNA could inhibit the proliferation and induce apoptosis of U87-EGFRv m glioma cells, which provides a theoretical foundation for studying the effect of e-Met and combined target therapy in glioma.
出处 《实用医学杂志》 CAS 北大核心 2013年第6期854-856,共3页 The Journal of Practical Medicine
基金 国家自然科学基金(编号:30973481 81272509) 广东省自然科学基金(编号:9151051501000053)
关键词 SIRNA c—Met 表皮生长因子受体 Ⅲ型突变体 siRNA c-Met EGFRv Ⅲ
  • 相关文献

参考文献5

  • 1ttatanpaa K J, Burma S, Zhao D, et al. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance [J]. Neoplasia, 2010, 12 (9) : 675 -684.
  • 2Yap T A, de Bono J S. Targeting the HGF/c-Met axis: state of play [J]. Mol Cancer Ther, 2010,9(5) : 1077-1079.
  • 3张兴梅,石玉生,陈明,夏许可,李树基,李晓文,曹东林.EGFRvⅢ的siRNA对胶质瘤细胞凋亡和增殖的影响[J].肿瘤防治研究,2011,38(9):975-978. 被引量:2
  • 4Gan H K, Kaye A H, Luwor R B. The EGFRv Ⅲ varianl in glioblastoma multiforme [J]. J Clin Neurosci, 2009,16 (6) : 748-754.
  • 5Lal B, Goodwin C R, Sang Y, et al. EGFRv Ⅲ and c-Met pathway inhibitors synergize against PTEN-nuII/EGFRv Ⅲ + glioblastonm xenografts [J]. Mol Cancer Ther, 2009,8 (7) : 1751-1760.

二级参考文献8

  • 1Gan HK,Kaye AH,Luwor RB. The EGFRvIII variant in glioblastoma multiforme [J]. J Clin Neurosci, 2009, 16 (6) : 748- 754.
  • 2Mukherjee B, McEllin B, Camacho CV, et al. EGFRv III and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma[J]. Cancer Res, 2009,69( 10): 4252-4259.
  • 3Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant Ill: a novel strategy for the therapy of malignant glioma[J]. Expert Rev Anticancer Ther, 2007,7(12 Suppl) :S45-S50.
  • 4Ji H,Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors[J]. Proc Natl Acad Sci U S A, 2006, 103 ( 20 ) : 7817-7822.
  • 5Yamoutpour F, Bodempudi V, Park SE, et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specif- ic cytotoxicity[J]. Mol Cancer Ther, 2008,7 ( 11 ) : 3586-3597.
  • 6Yiin J J, Hu B, Schornack PA, et al. ZD6474, a multitargeted in- hibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII,in the brain[J].Mol Cancer Ther,2010,9(4):929- 941.
  • 7Karpel-Massler G, Wirtz CR, Halatsch ME. Ribozyme-media- ted inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme[J]. Molecules, 2010,15 (7) : 4670-4678.
  • 8DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A ran- domized, double-blind, placebo-controlled study of an RNAi- based therapy directed against respiratory syneytial virus[J]. Proe Natl Acad Sci U S A, 2010,107(19) :8800-8805.

共引文献1

同被引文献19

  • 1王立生,刘福陆,贺福初,吴祖泽.纯化肝细胞生长因子对肝癌细胞的增殖刺激作用[J].高技术通讯,1995,5(8):48-50. 被引量:3
  • 2Zeng Q, Chen S, You Z, et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B.J Biol Chem, 2002, 277(28): 25203-25208.
  • 3Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res, 2012, 35(4): 595-604.
  • 4Shojaei F, Simmons BH, Lee JH, et al. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett, 2012, 320(1): 48-55.
  • 5Madonna R, Cevik C, Nasser M, et al. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. Thromb Haemost, 2012, 107(4): 656-661.
  • 6Stella GM, Benvenuti S, Gramaglia D, et al. Met mutations in cancers of unknown primary origin (CUPs). Hum Mutat, 2011, 32(1): 44-50.
  • 7Yap TA, Sandhu SK, Alam SM, et al. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets, 2011, 12(14): 2045-2058.
  • 8Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol, 2011, 3(1 Suppl): S21-S35.
  • 9Akasaka Y, Ono I, Yamashita T, et al. Basic fibroblast growth factor promotes apoptosis and suppresses granulation tissue formation in acute incisional wounds. J Pathol, 2004, 203(2): 710-720.
  • 10Cotrim P, Martelli-Junior H, Graner E, et al. Cyclosporin a induces proliferation in human gingival fibroblasts via induction of transforming growth factor-beta1.J Periodontol, 2003, 74(11): 1625-1633.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部